Ability Biologics uses its proprietary AbiLeap™ platform, which combines generative AI with a large, machine‑learning‑ready antibody interaction database, to design fully human, IgG‑based multispecific antibodies that bind only under specific cellular microenvironment signals. These logic‑gated antibodies provide heightened selectivity and potency for immune modulation in cancer and autoimmune diseases, enabling faster preclinical development of targeted biotherapeutics.
Funding
$18M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AVFounders
Product
Problem
Current antibody therapeutics often lack sufficient specificity, leading to off‑target effects and limited therapeutic windows in cancer and autoimmune diseases. Developing highly selective, context‑dependent antibodies is time‑consuming and costly with traditional discovery methods.
Solution
Ability leverages its proprietary AbiLeap™ platform, which combines generative artificial intelligence with a large, machine‑learning‑ready database of antigen‑antibody interactions, to design fully human, IgG‑based multispecific antibodies that bind only under defined cellular microenvironment signals. These “logic‑gated” antibodies can engage specific immune pathways while ignoring healthy tissues, providing greater potency and safety. The platform rapidly generates libraries of candidate antibodies with exquisite affinity and selectivity, accelerating preclinical development of immune modulators for oncology and auto‑immune indications. Ability advances multiple candidates through human proof‑of‑concept studies, aiming to deliver next‑generation targeted biotherapeutics to address unmet medical needs.
Target Audience
Primary customers are pharmaceutical and biotechnology companies developing immuno‑oncology or autoimmune therapies that require highly selective antibody candidates.
Features
- Generative AI‑driven discovery engine (AbiLeap™) that designs fully human multispecific antibodies with contextual binding logic
- Massive curated database of antigen‑antibody interactions enabling rapid generation of high‑affinity, selective candidates
- Contextually gated antibody format that activates only in specific cellular microenvironments, improving therapeutic index
- Ability to target both immune subpopulations and tumor‑associated antigens within a single molecule
- End‑to‑end pipeline from in silico design to preclinical proof‑of‑concept, shortening development timelines
- Focus on IgG‑based formats compatible with standard manufacturing and clinical deployment